Although the first patents for Gabitril (tiagabine hydrochloride) have expired, no generic versions are available at this time. However, the drug's next patent is set to expire in April 2016. It's possible that a generic version could be introduced after this date, barring any lawsuits or other patents for specific uses of the drug.
Generic Gabitril: An OverviewGabitril® (tiagabine hydrochloride) is a prescription medication that is used to treat epilepsy. In particular, the drug is approved to be used with other seizure medications to treat certain types of seizures (partial seizures or focal seizures) in people with epilepsy.
Gabitril is manufactured by Cephalon, Inc. This epilepsy medication is currently under the protection of a patent that prevents any generic Gabitril from being manufactured in the United States.
When Will Generic Gabitril Be Available?
The first patents for Gabitril expired in September 2011 and March 2012, yet no generic versions are available. This suggests that later-expiring patents are still protecting the drug from generic competition. The next Gabitril patent will expire in April 2016.
At this point, this is the earliest possible date that a generic version of the drug could become available. However, circumstances could extend this exclusivity period beyond 2016. This could include such things as lawsuits or other patents for specific Gabitril uses. Once the patent expires, several companies will likely begin manufacturing generic Gabitril.